Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration

Pharmacokinetics and pharmacodynamics ofnab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel

(2014) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors

(2013) L. Zhang et al.   CLINICAL CANCER RESEARCH

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

(2013) Cosimo Commisso et al.   NATURE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer

(2012) Kristopher K. Frese et al.   Cancer Discovery

Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis

(2011) Ta-Chen Huang et al.   CANCER TREATMENT REVIEWS

Delivering nanomedicine to solid tumors

(2010) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Protein nanoparticles as drug carriers in clinical medicine

(2008) Michael J. Hawkins et al.   ADVANCED DRUG DELIVERY REVIEWS

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

(2008) E. R. Gardner et al.   CLINICAL CANCER RESEARCH

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY